Vascular Biogenics Ltd. (NASDAQ:VBLT) is set to post its quarterly earnings results before the market opens on Wednesday, November 8th. Analysts expect Vascular Biogenics to post earnings of ($0.21) per share for the quarter.

Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. On average, analysts expect Vascular Biogenics to post $-0.81 EPS for the current fiscal year and $-0.78 EPS for the next fiscal year.

Vascular Biogenics Ltd. (VBLT) opened at 6.10 on Wednesday. Vascular Biogenics Ltd. has a 12-month low of $3.90 and a 12-month high of $7.25. The firm’s market capitalization is $164.75 million. The firm has a 50-day moving average of $6.02 and a 200 day moving average of $5.27.

Several research firms have issued reports on VBLT. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Vascular Biogenics in a research note on Tuesday, October 3rd. Finally, ValuEngine cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.75.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with's FREE daily email newsletter.